

Binfeng Lu

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6138953/publications.pdf>

Version: 2024-02-01

48
papers

10,262
citations

257357

24
h-index

243529

44
g-index

49
all docs

49
docs citations

49
times ranked

23489
citing authors

#	ARTICLE	IF	CITATIONS
1	Chronic Activation of LXR β Sensitizes Mice to Hepatocellular Carcinoma. <i>Hepatology Communications</i> , 2022, 6, 1123-1139.	2.0	5
2	Autologous Cytokine-Induced Killer Cell Immunotherapy Enhances Chemotherapy Efficacy against Multidrug-Resistant Tuberculosis. <i>Journal of Immunology Research</i> , 2022, 2022, 1-10.	0.9	0
3	The IL-1 family in tumorigenesis and antitumor immunity. <i>Seminars in Cancer Biology</i> , 2022, 86, 280-295.	4.3	22
4	Eomes Impedes Durable Response to Tumor Immunotherapy by Inhibiting Stemness, Tissue Residency, and Promoting the Dysfunctional State of Intratumoral CD8+ T Cells. <i>Frontiers in Cell and Developmental Biology</i> , 2021, 9, 640224.	1.8	13
5	LincRNA-immunity landscape analysis identifies EPIC1 as a regulator of tumor immune evasion and immunotherapy resistance. <i>Science Advances</i> , 2021, 7, .	4.7	28
6	A novel immunochemotherapy based on targeting of cyclooxygenase and induction of immunogenic cell death. <i>Biomaterials</i> , 2021, 270, 120708.	5.7	14
7	Development and application of sensitive, specific, and rapid CRISPR-Cas13a-based diagnosis. <i>Journal of Medical Virology</i> , 2021, 93, 4198-4204.	2.5	20
8	Farnesylthiosalicylic acid-derivatized PEI-based nanocomplex for improved tumor vaccination. <i>Molecular Therapy - Nucleic Acids</i> , 2021, 26, 594-602.	2.3	6
9	The Half-Life-Extended IL21 can Be Combined With Multiple Checkpoint Inhibitors for Tumor Immunotherapy. <i>Frontiers in Cell and Developmental Biology</i> , 2021, 9, 779865.	1.8	11
10	Targeting metabotropic glutamate receptor 4 for cancer immunotherapy. <i>Science Advances</i> , 2021, 7, eabj4226.	4.7	11
11	Triple drugs co-delivered by a small gemcitabine-based carrier for pancreatic cancer immunochemotherapy. <i>Acta Biomaterialia</i> , 2020, 106, 289-300.	4.1	29
12	Immune suppressed tumor microenvironment by exosomes derived from gastric cancer cells via modulating immune functions. <i>Scientific Reports</i> , 2020, 10, 14749.	1.6	44
13	Tumor-Derived IL33 Promotes Tissue-Resident CD8+ T Cells and Is Required for Checkpoint Blockade Tumor Immunotherapy. <i>Cancer Immunology Research</i> , 2020, 8, 1381-1392.	1.6	26
14	Checkpoint molecules coordinately restrain hyperactivated effector T cells in the tumor microenvironment. <i>Oncotmunology</i> , 2020, 9, 1708064.	2.1	33
15	IL36 Cooperates With Anti-CTLA-4 mAbs to Facilitate Antitumor Immune Responses. <i>Frontiers in Immunology</i> , 2020, 11, 634.	2.2	21
16	CD8+ T cells located in tertiary lymphoid structures are associated with improved prognosis in patients with gastric cancer. <i>Oncology Letters</i> , 2020, 20, 2655-2664.	0.8	13
17	Differential Requirement of Beclin 1 for Regulating the Balance of Naïve and Activated CD4+ T Cells. <i>Frontiers in Cell and Developmental Biology</i> , 2020, 8, 834.	1.8	2
18	Inhibition of histone lysine-specific demethylase 1 elicits breast tumor immunity and enhances antitumor efficacy of immune checkpoint blockade. <i>Oncogene</i> , 2019, 38, 390-405.	2.6	149

#	ARTICLE	IF	CITATIONS
19	IL-36 ¹² Promotes CD8 ⁺ T Cell Activation and Antitumor Immune Responses by Activating mTORC1. <i>Frontiers in Immunology</i> , 2019, 10, 1803.	2.2	23
20	Dual functional immunostimulatory polymeric prodrug carrier with pendent indoximod for enhanced cancer immunochemotherapy. <i>Acta Biomaterialia</i> , 2019, 90, 300-313.	4.1	50
21	B7-H3 promotes aerobic glycolysis and chemoresistance in colorectal cancer cells by regulating HK2. <i>Cell Death and Disease</i> , 2019, 10, 308.	2.7	143
22	Targeted codelivery of doxorubicin and IL-36 ¹³ expression plasmid for an optimal chemo-gene combination therapy against cancer lung metastasis. <i>Nanomedicine: Nanotechnology, Biology, and Medicine</i> , 2019, 15, 129-141.	1.7	28
23	Novel Effector Phenotype of Tim-3 ⁺ Regulatory T Cells Leads to Enhanced Suppressive Function in Head and Neck Cancer Patients. <i>Clinical Cancer Research</i> , 2018, 24, 4529-4538.	3.2	82
24	Improved Cancer Immunochemotherapy via Optimal Co-delivery of Chemotherapeutic and Immunomodulatory Agents. <i>Molecular Pharmaceutics</i> , 2018, 15, 5162-5173.	2.3	20
25	ATF4 Regulates CD4 ⁺ T Cell Immune Responses through Metabolic Reprogramming. <i>Cell Reports</i> , 2018, 23, 1754-1766.	2.9	69
26	Lower expression level of IL-33 is associated with poor prognosis of pulmonary adenocarcinoma. <i>PLoS ONE</i> , 2018, 13, e0193428.	1.1	32
27	ST2/IL-33-Dependent Microglial Response Limits Acute Ischemic Brain Injury. <i>Journal of Neuroscience</i> , 2017, 37, 4692-4704.	1.7	169
28	Interleukin-33 Expression does not Correlate with Survival of Gastric Cancer Patients. <i>Pathology and Oncology Research</i> , 2017, 23, 615-619.	0.9	9
29	PD-L1 Expression Promotes Epithelial to Mesenchymal Transition in Human Esophageal Cancer. <i>Cellular Physiology and Biochemistry</i> , 2017, 42, 2267-2280.	1.1	92
30	Peripheral Deletion of CD8 T Cells Requires p38 MAPK in Cross-Presenting Dendritic Cells. <i>Journal of Immunology</i> , 2017, 199, 2713-2720.	0.4	0
31	High mRNA expression level of IL-6R was associated with better prognosis for patients with ovarian cancer: a pooled meta-analysis. <i>Scientific Reports</i> , 2017, 7, 8769.	1.6	7
32	Ginsenoside PPD TM 's Antitumor Effect via Down-Regulation of mTOR Revealed by Super-Resolution Imaging. <i>Molecules</i> , 2017, 22, 486.	1.7	12
33	TIM-3 as a Target for Cancer Immunotherapy and Mechanisms of Action. <i>International Journal of Molecular Sciences</i> , 2017, 18, 645.	1.8	193
34	PD-1 Blockade Boosts Radiofrequency Ablation TM -Elicited Adaptive Immune Responses against Tumor. <i>Clinical Cancer Research</i> , 2016, 22, 1173-1184.	3.2	207
35	Guidelines for the use and interpretation of assays for monitoring autophagy (3rd edition). <i>Autophagy</i> , 2016, 12, 1-222.	4.3	4,701
36	Interleukin-33 in tumorigenesis, tumor immune evasion, and cancer immunotherapy. <i>Journal of Molecular Medicine</i> , 2016, 94, 535-543.	1.7	81

#	ARTICLE	IF	CITATIONS
37	IL-36 ¹³ Transforms the Tumor Microenvironment and Promotes Type 1 Lymphocyte-Mediated Antitumor Immune Responses. <i>Cancer Cell</i> , 2015, 28, 296-306.	7.7	93
38	Tumoral Expression of IL-33 Inhibits Tumor Growth and Modifies the Tumor Microenvironment through CD8+ T and NK Cells. <i>Journal of Immunology</i> , 2015, 194, 438-445.	0.4	185
39	An Increased Abundance of Tumor-Infiltrating Regulatory T Cells Is Correlated with the Progression and Prognosis of Pancreatic Ductal Adenocarcinoma. <i>PLoS ONE</i> , 2014, 9, e91551.	1.1	169
40	Impeded Nedd4-1-Mediated Ras Degradation Underlies Ras-Driven Tumorigenesis. <i>Cell Reports</i> , 2014, 7, 871-882.	2.9	66
41	Too Much of a Good Thing? Tim-3 and TCR Signaling in T Cell Exhaustion. <i>Journal of Immunology</i> , 2014, 193, 1525-1530.	0.4	149
42	Guidelines for the use and interpretation of assays for monitoring autophagy. <i>Autophagy</i> , 2012, 8, 445-544.	4.3	3,122
43	T-cell-mediated tumor immune surveillance and expression of B7 co-inhibitory molecules in cancers of the upper gastrointestinal tract. <i>Immunologic Research</i> , 2011, 50, 269-275.	1.3	64
44	An Essential Role of the RNA Editing Enzyme ADAR1 in T Cell Development.. <i>Blood</i> , 2009, 114, 917-917.	0.6	1
45	IL-17 helps autoimmune th1 responses. <i>FASEB Journal</i> , 2008, 22, 1073.24.	0.2	0
46	Gadd45 ¹² Is Important for CD8+T Cell Mediated Tumor Surveillance. <i>FASEB Journal</i> , 2008, 22, 1078.10.	0.2	0
47	Autophagy Induction and Autophagic Cell Death in Effector T Cells. <i>Autophagy</i> , 2007, 3, 158-159.	4.3	18
48	The Molecular Mechanisms That Control Function and Death of Effector CD4 ⁺ T Cells. <i>Immunologic Research</i> , 2006, 36, 275-282.	1.3	30